A Phase 3 interventional study of Formoterol Turbuhaler® 4.5mg and Formoterol Turbuhaler® 9 mg in Chronic Obstructive Pulmonary Disease, sponsored by AstraZeneca. Completed at 48 sites in 5 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2012-10-25.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 89 studies testing formoterol in Pulmonary Disease, Chronic Obstructive — 3 open to participants now, 3 under way, 1 of them phase 3. formoterol · Pulmonary Disease, Chronic Obstructive.
Among the 89 studies testing formoterol in Pulmonary Disease, Chronic Obstructive, this one is the 26th largest by enrollment, is one of 5 that started in 2007, is one of 40 in phase 3, and was the 20th registered.
5,527 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →3 of the 89 studies testing formoterol in Pulmonary Disease, Chronic Obstructive are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in Germany, United Kingdom
Ages 40–80
AstraZeneca · Sites in United States, Argentina, Australia and 34 more countries
Ages 40–80
University of Tennessee Graduate School of Medicine · Sites in United States
Ages 40+
By country, each count listing its studies:
formoterol: first FDA approval 2001 (FORADIL), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 561 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
89 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 5 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 613 is above the median of 62 across 3,845 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 120 across the 89 interventional studies. Of the 80 that completed or were terminated, 38 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
68 of 89 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,505 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca: 14 open now, 15 under way, 4 of them phase 3. Of 264 finished, 127 (48%) have results posted.
Among the 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca, this one is the 54th largest by enrollment of the 194 interventional ones that give a count, is one of 9 that started in 2007, is one of 76 in phase 3, and was the 28th registered.
AstraZeneca’s Pulmonary Disease, Chronic Obstructive studies by the year they started, since 1999.
1 of the studies testing formoterol in Pulmonary Disease, Chronic Obstructive that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07073950AstraZenecaA Study to Investigate the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Compared With Placebo MDI on Heart and Lung Function in Participants With Chronic Obstructive Pulmonary Disease (COPD) and Hyperinflation | 2027-05-31 |
Add it to your calendar (.ics) → With an account.
Among the 89 studies testing formoterol in Pulmonary Disease, Chronic Obstructive, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AstraZeneca’s 284 in Pulmonary Disease, Chronic Obstructive:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to show the efficacy and safety of formoterol for the maintenance treatment of patients with COPD compared with placebo in patients in Japan and in European countries during 12 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Formoterol 4.5 ug twice daily (bid)
Drug: Formoterol Turbuhaler® 4.5mg
Formoterol 9.0 ug bid
Drug: Formoterol Turbuhaler® 9 mg
Placebo
Drug: Turbuhaler® placebo
4.5 mg inhaled twice daily
Also known as: Oxis
9 mg inhaled twice daily
Also known as: Oxis
placebo inhaled twice daily
Forced Expiratory Volume in 1 Second (FEV1; L) 60 Minutes Post-dose
FEV1 (expressed as litres \[L\]) is a spirometric measure of lung function. FEV1 was measured 60 minutes after administration of study drug. The results are expressed as a percentage in relation to the baseline value.
Time frame: from baseline up to 12 weeks
Forced Vital Capacity (FVC) 60 Minutes Post-dose
Forced Vital Capacity (FVC) is a spirometric measure of lung function. FVC was measured 60 minutes after administration of study drug. The results are expressed as a percentage in relation to the baseline value
Time frame: from baseline up to 12 weeks
FEV1 Pre-dose
Lung function (FEV1) was measured before administrations of the study drug (pre-dose). The results are expressed as a percentage of mean FEV1 over visists 4-6 in relation to the baseline (visit 3) value
Time frame: baseline at week 0 and pre-dose at weeks 4, 8 and 12
FVC Pre-dose
Lung function (FVC) was measured before administrations of the study drug (pre-dose). The results are expressed as a percentage of mean FEV1 over visists 4-6 in relation to the baseline (visit 3) value
Time frame: baseline at week 0 and pre-dose at weeks 4, 8 and 12
FEV1 5 Minutes Post-dose
Lung function (FEV1) was measured 5 minutes after the first dose of study drug. The results are expressed as a percentage in relation to the baseline value
Time frame: baseline and 5 minutes anter first dose
FVC 5 Minutes Post-dose
Lung function (FVC) was measured 5 minutes after the first dose of study drug, The results are expressed as a percentage in relation to the baseline value
Time frame: baseline and 5 minutes anter first dose
Change in Peak Expiratory Flow (PEF), Morning
Patients were asked to measure and record lung function (peak expiratory flow \[PEF\] measured in the morning). Average values over the last 10 days of the run-in period and the whole treatment period were calculated. The results are expressed as the change from the run-in period average value
Time frame: run-in period and 12 week
Change in Peak Expiratory Flow (PEF), Evening
Patients were asked to measure and record lung function (peak expiratory flow \[PEF\] measured in the evening). Average values over the last 10 days of the run-in period and the whole treatment period were calculated. The results are expressed as the change from the run-in period average value
Time frame: run-in period and 12 week
Change in Night-time Awakenings Due to Symptoms
Patients were asked to record the night-time awakenings due to symptoms (scored from 0-4 with 4 being the most severe). Period averages over the last 10 days of the run-in period and the whole treatment period were calculated. The results are expressed as the change from the run-in period average value
Time frame: run-in period up to 12 weeks
Breathlessness
Patients were asked to record breathlessness (scored from 0-4 with 4 being the most severe). Period averages over the last 10 days of the run-in period and the whole treatment period were calculated. The results are expressed as the change from the run-in period average value
Time frame: run-in period up to 12 weeks
Cough
Patients were asked to record cough (scored from 0-4 with 4 being the most severe). Period averages over the last 10 days of the run-in period and the whole treatment period were calculated. The results are expressed as the change from the run-in period average value
Time frame: run-in period up to 12 weeks
Use of Reliever Medication
Patients were asked to record reliever medication use. Period averages over the last 10 days of the run-in period and the whole treatment period were calculated. The results are expressed as the change from the run-in period average value
Time frame: 12 weeks (end of run-in to last visit)
St George's Respiratory Questionnaire (SGRQ)
Patients were asked to complete the St George's Respiratory Questionnaire (SGRQ). Subscale symptom score ranges from 0 to 100% and measures the effect of respiratory symptoms, frequency, and severity on quality of life. A score of 0 indicates the best possible status. Results are expressed as the change from baseline score with a decrease in score indicating improvement.
Time frame: 12 weeks (end of run-in to last visit)
Outpatients, male or female aged ≥ 40 years with moderate to severe chronic obstructive pulmonary disease (COPD). 766 subjects enrolled; 153 excluded: 96 for incorrect enrollment, 17 for adverse events, 32 for voluntary discontinuation, 1 for non-compliance with protocol, 7 for other reasons. 613 were randomised.
| Milestone | Formoterol 4.5 Bid | Formoterol 9.0 Bid | Placebo |
|---|---|---|---|
| Started | 206 | 199 | 208 |
| Completed | 195 | 182 | 186 |
| Not completed | 11 | 17 | 22 |
| Withdrew: Adverse event | 6 | 8 | 10 |
| Withdrew: Withdrawal by subject | 4 | 6 | 11 |
| Withdrew: Lost to follow-up | 0 | 2 | 1 |
| Withdrew: Protocol violation | 1 | 0 | 0 |
| Withdrew: Copd exacerbation | 0 | 1 | 0 |
FEV1 (expressed as litres \[L\]) is a spirometric measure of lung function. FEV1 was measured 60 minutes after administration of study drug. The results are expressed as a percentage in relation to the baseline value.
| percent of baseline | Formoterol 4.5 Bid | Formoterol 9.0 Bid | Placebo |
|---|---|---|---|
| Forced Expiratory Volume in 1 Second (FEV1; L) 60 Minutes Post-dose | 112.9 (75.1 to 177.0) | 113.36 (66.2 to 184.0) | 101.28 (58.3 to 189.1) |
Forced Vital Capacity (FVC) is a spirometric measure of lung function. FVC was measured 60 minutes after administration of study drug. The results are expressed as a percentage in relation to the baseline value
| percent of baseline | Formoterol 4.5 Bid | Formoterol 9.0 Bid | Placebo |
|---|---|---|---|
| Forced Vital Capacity (FVC) 60 Minutes Post-dose | 109.73 (81.2 to 162.0) | 109.92 (83.2 to 200.9) | 102.11 (71.2 to 212.7) |
Lung function (FEV1) was measured before administrations of the study drug (pre-dose). The results are expressed as a percentage of mean FEV1 over visists 4-6 in relation to the baseline (visit 3) value
| percent of baseline | Formoterol 4.5 Bid | Formoterol 9.0 Bid | Placebo |
|---|---|---|---|
| FEV1 Pre-dose | 104.54 (73.3 to 175.0) | 104.65 (71.0 to 172.6) | 99.77 (56.5 to 183.6) |
Lung function (FVC) was measured before administrations of the study drug (pre-dose). The results are expressed as a percentage of mean FEV1 over visists 4-6 in relation to the baseline (visit 3) value
| percent of baseline | Formoterol 4.5 Bid | Formoterol 9.0 Bid | Placebo |
|---|---|---|---|
| FVC Pre-dose | 103.62 (77.7 to 149.8) | 103.36 (68.9 to 162.7) | 100.73 (70.8 to 211.9) |
Lung function (FEV1) was measured 5 minutes after the first dose of study drug. The results are expressed as a percentage in relation to the baseline value
| percent of baseline | Formoterol 4.5 Bid | Formoterol 9.0 Bid | Placebo |
|---|---|---|---|
| FEV1 5 Minutes Post-dose | 110.16 (65.6 to 156.5) | 110.24 (80.6 to 155.1) | 101.25 (79.4 to 121.6) |
Lung function (FVC) was measured 5 minutes after the first dose of study drug, The results are expressed as a percentage in relation to the baseline value
| percent of baseline | Formoterol 4.5 Bid | Formoterol 9.0 Bid | Placebo |
|---|---|---|---|
| FVC 5 Minutes Post-dose | 108.50 (89.9 to 143.2) | 108.88 (81.5 to 153.4) | 101.59 (84.3 to 124.7) |
Patients were asked to measure and record lung function (peak expiratory flow \[PEF\] measured in the morning). Average values over the last 10 days of the run-in period and the whole treatment period were calculated. The results are expressed as the change from the run-in period average value
| L/min | Formoterol 4.5 Bid | Formoterol 9.0 Bid | Placebo |
|---|---|---|---|
| Change in Peak Expiratory Flow (PEF), Morning | 16.27 ± 27.90 | 18.34 ± 26.19 | 3.60 ± 27.08 |
Patients were asked to measure and record lung function (peak expiratory flow \[PEF\] measured in the evening). Average values over the last 10 days of the run-in period and the whole treatment period were calculated. The results are expressed as the change from the run-in period average value
| L/min | Formoterol 4.5 Bid | Formoterol 9.0 Bid | Placebo |
|---|---|---|---|
| Change in Peak Expiratory Flow (PEF), Evening | 13.15 ± 27.52 | 15.76 ± 25.22 | 2.36 ± 26.43 |
Patients were asked to record the night-time awakenings due to symptoms (scored from 0-4 with 4 being the most severe). Period averages over the last 10 days of the run-in period and the whole treatment period were calculated. The results are expressed as the change from the run-in period average value
| scores on a scale per day | Formoterol 4.5 Bid | Formoterol 9.0 Bid | Placebo |
|---|---|---|---|
| Change in Night-time Awakenings Due to Symptoms | -0.1318 ± 0.4791 | -0.1748 ± 0.5517 | -0.0466 ± 0.4900 |
Patients were asked to record breathlessness (scored from 0-4 with 4 being the most severe). Period averages over the last 10 days of the run-in period and the whole treatment period were calculated. The results are expressed as the change from the run-in period average value
| scores on a scale per day | Formoterol 4.5 Bid | Formoterol 9.0 Bid | Placebo |
|---|---|---|---|
| Breathlessness | -0.4068 ± 0.6193 | -0.4531 ± 0.5511 | -0.2626 ± 0.5899 |
Patients were asked to record cough (scored from 0-4 with 4 being the most severe). Period averages over the last 10 days of the run-in period and the whole treatment period were calculated. The results are expressed as the change from the run-in period average value
| scores on a scale per day | Formoterol 4.5 Bid | Formoterol 9.0 Bid | Placebo |
|---|---|---|---|
| Cough | -0.3250 ± 0.6424 | -0.4088 ± 0.6374 | -0.2016 ± 0.6233 |
Patients were asked to record reliever medication use. Period averages over the last 10 days of the run-in period and the whole treatment period were calculated. The results are expressed as the change from the run-in period average value
| medication doses per day | Formoterol 4.5 Bid | Formoterol 9.0 Bid | Placebo |
|---|---|---|---|
| Use of Reliever Medication | -0.60 ± 1.47 | -0.97 ± 1.88 | -0.23 ± 1.25 |
Patients were asked to complete the St George's Respiratory Questionnaire (SGRQ). Subscale symptom score ranges from 0 to 100% and measures the effect of respiratory symptoms, frequency, and severity on quality of life. A score of 0 indicates the best possible status. Results are expressed as the change from baseline score with a decrease in score indicating improvement.
| Scores on a scale | Formoterol 4.5 Bid | Formoterol 9.0 Bid | Placebo |
|---|---|---|---|
| St George's Respiratory Questionnaire (SGRQ) | -5.46 ± 12.12 | -6.38 ± 10.77 | -2.02 ± 12.98 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Formoterol 4.5 Bid | — | 6/206 (2.9%) | 33/206 (16%) |
| Formoterol 9.0 Bid | — | 7/199 (3.5%) | 31/199 (15.6%) |
| Placebo | — | 4/208 (1.9%) | 31/208 (14.9%) |
| Event | Formoterol 4.5 Bid | Formoterol 9.0 Bid | Placebo |
|---|---|---|---|
| PneumoniaInfections and infestations | 2/206 | 2/199 | 0/208 |
| Chronic Obstructive Pulmonary DiseaseRespiratory, thoracic and mediastinal disorders | 0/206 | 1/199 | 2/208 |
| Lobar PneumoniaInfections and infestations | 0/206 | 1/199 | 0/208 |
| Gastric CancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/206 | 1/199 | 0/208 |
| Hypoglycaemic UnconsciousnessMetabolism and nutrition disorders | 0/206 | 1/199 | 0/208 |
| Angina PectorisCardiac disorders | 0/206 | 1/199 | 0/208 |
| DeathGeneral disorders | 1/206 | 0/199 | 0/208 |
| Prostate CanerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/206 | 0/199 | 0/208 |
| Diabetes MellitusMetabolism and nutrition disorders | 1/206 | 0/199 | 0/208 |
| Cardiopulmonary FailureCardiac disorders | 1/206 | 0/199 | 0/208 |
| Event | Formoterol 4.5 Bid | Formoterol 9.0 Bid | Placebo |
|---|---|---|---|
| NasopharyngitisInfections and infestations | 24/206 | 25/199 | 20/208 |
| Chronic Obstructive Pulmonary DiseaseRespiratory, thoracic and mediastinal disorders | 10/206 | 7/199 | 15/208 |
| Age Continuous(Years) | Formoterol 4.5 Bid | Formoterol 9.0 Bid | Placebo | Total |
|---|---|---|---|---|
| Mean | 66.7 ± 9.4 | 67.2 ± 9.2 | 66.3 ± 9.7 | 66.75 ± 9.4 |
| Sex: Female, Male(Participants) | Formoterol 4.5 Bid | Formoterol 9.0 Bid | Placebo | Total |
|---|---|---|---|---|
| Female | 23 | 29 | 22 | 74 |
| Male | 183 | 170 | 186 | 539 |
The record gives a start of Dec 2007, a primary completion of Apr 2009 and a completion of Apr 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2012, 3 years 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Formoterol
Pulmonary Disease, Chronic Obstructive →